At the time of writing, RAPT Therapeutics Inc [RAPT] stock is trading at $8.43, down -13.36%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RAPT shares have gain 13.46% over the last week, with a monthly amount glided 8.31%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on December 26, 2024, and kept the price target unchanged to $10. On November 13, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on November 11, 2024. JP Morgan downgraded its rating to a Underweight. Wolfe Research downgraded its rating to Peer Perform for this stock on May 14, 2024. In a note dated May 10, 2024, Guggenheim downgraded an Neutral rating on this stock.
For the past year, the stock price of RAPT Therapeutics Inc fluctuated between $5.67 and $30.60. Currently, Wall Street analysts expect the stock to reach $30.71 within the next 12 months. RAPT Therapeutics Inc [NASDAQ: RAPT] shares were valued at $8.43 at the most recent close of the market. An investor can expect a potential return of 264.29% based on the average RAPT price forecast.
Analyzing the RAPT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -0.81 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.83 points at the first support level, and at 7.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.43, and for the 2nd resistance point, it is at 10.44.
Ratios To Look Out For
It is important to note that RAPT Therapeutics Inc [NASDAQ:RAPT] has a current ratio of 21.11. As well, the Quick Ratio is 21.11, while the Cash Ratio is 6.94.
